J. Mertz

发表

Conformational changes in cholera toxin B subunit-ganglioside GM1 complexes are elicited by environmental pH and evoke changes in membrane structure.

J. McCann, J. Mertz, J. Czworkowski, 1997, Biochemistry.

Targeting MYC dependence in cancer by inhibiting BET bromodomains

P. Sandy, R. Sims, Deanna A. Mele, 2011, Proceedings of the National Academy of Sciences.

Development of methyl isoxazoleazepines as inhibitors of BET.

R. Cummings, P. Sandy, Y. Leblanc, 2015, Bioorganic & medicinal chemistry letters.

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.

P. Sandy, Y. Leblanc, H. Jayaram, 2016, Journal of medicinal chemistry.

Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma

R. Sims, N. Raje, A. Yee, 2017, Leukemia.

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.

Patricia Greninger, C. Benes, A. Amzallag, 2016, Cancer research.

MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial

P. Trojer, M. Salama, S. Verstovsek, 2021 .

Fluorescence analysis of galactose, lactose, and fucose interaction with the cholera toxin B subunit.

J. McCann, J. Mertz, W. Picking, 1996, Biochemical and biophysical research communications.

Selection for c-myc Integration Sites in Polyclonal T-Cell Lymphomas

M. Lozano, J. Dudley, J. Mertz, 2002, Journal of Virology.

Retroviral Rem protein requires processing by signal peptidase and retrotranslocation for nuclear function

M. Lozano, J. Dudley, J. Mertz, 2010, Proceedings of the National Academy of Sciences.

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.

P. Sandy, Y. Leblanc, H. Jayaram, 2013, ACS medicinal chemistry letters.

Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains.

P. Sandy, Y. Leblanc, H. Jayaram, 2016, ACS medicinal chemistry letters.

Endogenous Retroviruses and Cancer

C. Kozak, M. Palmarini, J. Dudley, 2010 .

Mouse Mammary Tumor Virus Encodes a Self-Regulatory RNA Export Protein and Is a Complex Retrovirus

M. Lozano, J. Dudley, J. Mertz, 2005, Journal of Virology.

Identification and characterization of the T-cell-specific enhancer of type B leukemogenic virus

J. Mertz, 2003 .

Rev and Rex proteins of human complex retroviruses function with the MMTV Rem-responsive element

M. Lozano, J. Dudley, J. Mertz, 2009, Retrovirology.

Cloning, expression, and affinity purification of recombinant Shigella flexneri invasion plasmid antigens IpaB and IpaC.

J. Mertz, W. Picking, W. Picking, 1996, Protein expression and purification.

Mapping of the Functional Boundaries and Secondary Structure of the Mouse Mammary Tumor Virus Rem-responsive Element*

Rick Russell, R. Russell, J. Dudley, 2009, The Journal of Biological Chemistry.

ALY Is a Common Coactivator of RUNX1 and c-Myb on the Type B Leukemogenic VirusEnhancer

J. Dudley, J. Mertz, R. Kobayashi, 2007, Journal of Virology.

Type B Leukemogenic Virus Has a T-Cell-Specific Enhancer That Binds AML-1

J. Dudley, J. Mertz, F. Mustafa, 2001, Journal of Virology.

Streptobacillus moniliformis isolated from a case of Haverhill fever: biochemical characterization and inhibitory effect of sodium polyanethol sulfonate.

J. Mertz, P. Stewart, D. Lambe, 1973, American journal of clinical pathology.

A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma

I. Flinn, M. Maris, R. Sims, 2018 .

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition*

G. Hatzivassiliou, P. Sandy, H. Jayaram, 2016, The Journal of Biological Chemistry.

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

I. Flinn, M. Maris, R. Sims, 2015 .

Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment

K. Lillemoe, M. Mino‐Kenudson, R. Sims, 2016, Clinical Cancer Research.

Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity

P. Trojer, R. Sims, Shilpi Arora, 2021, The Journal of biological chemistry.

FLUORESCENT ANTIBODY DETECTION OF HUMAN OCCURRENCE OF AN UNCLASSIFIED BACTERIAL GROUP CAUSING ENDOCARDITIS.

J. Mertz, I. J. Slotnick, M. Dougherty, 1964, The Journal of infectious diseases.

Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Karen E Gascoigne, P. Sandy, R. Sims, 2016, eLife.

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Karen E Gascoigne, P. Sandy, R. Sims, 2016, eLife.

Drosophila as a Model for Photoreceptor Dystrophies and Cell Death

W. Stark, J. Mertz, De‐Mao Chen, 1995 .

ALY Is a Common Coactivator of RUNX1 and c-Myb on the Type B Leukemogenic Virus Enhancer (cid:1)

R. Kobayashi, J. Dudley, J. Mertz, 2007 .

Identification of Epitope and Surface-Exposed Domains of Shigella flexneri Invasion Plasmid Antigen D (IpaD)

J. Mertz, C. Mallett, E. Oaks, 1998, Infection and Immunity.

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

R. Sims, N. Raje, J. Mertz, 2015 .

A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).

P. Trojer, S. Verstovsek, R. Hoffman, 2019, Journal of Clinical Oncology.

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

B. Leber, P. Trojer, S. Verstovsek, 2019, Blood.

Abstract 4749: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Karen E Gascoigne, R. Sims, J. Mertz, 2016 .

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.

P. Sandy, Y. Leblanc, H. Jayaram, 2013, ACS medicinal chemistry letters.

A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF)

S. Verstovsek, R. Hoffman, A. Senderowicz, 2018, Blood.